The role of eCIRP in bleomycin-induced pulmonary fibrosis in mice.

OBJECTIVE AND
DESIGN: We examined the role of eCIRP in the pathogenesis of bleomycin-induced pulmonary fibrosis (PF).
MATERIAL AND METHODS: Publicly available gene expression omnibus datasets were analyzed for the expression of CIRP in lung samples from patients with PF. Wild type (WT) or CIRP-/- mice received daily injections of 10 μg/g bleomycin for 10 days. A subset of bleomycin-injected WT mice was treated with the eCIRP antagonist C23 (8 μg/g/day) from day 10 to day 19. At three weeks, transthoracic echocardiography was performed to measure the degree of pulmonary hypertension, and lung tissues were collected and analyzed for markers of fibrosis.
RESULTS: Analysis of the mRNA data of human lung samples showed a significant positive correlation between CIRP and α-smooth muscle actin (α-SMA), an important marker of fibrosis. Moreover, the expression of CIRP was higher in patients with acute exacerbation of PF than in patients with stable PF. CIRP-/- mice showed attenuated induction of α-SMA and collagens (Col1a1, Col3a1), reduced hydroxyproline content, decreased histological fibrosis scores, and improved pulmonary hypertension as compared to WT mice. WT mice treated with C23 also had significant attenuation of the above endpoint measure.
CONCLUSIONS: Our study demonstrates that eCIRP plays a key role in promoting the development of PF, and blocking eCIRP with C23 can significantly attenuate this process.

Introduction

Pulmonary fibrosis (PF), characterized by unrestrained production and accumulation of extracellular matrix components, is a pathology common in many chronic lung diseases such as idiopathic PF (IPF), sarcoidosis, and systemic sclerosis. Chronic inflammation caused by inhalation of foreign particles and autoimmune disease often results in PF [1, 2], although a causal role for inflammation has not been determined in IPF [3]. Irrespective of its etiology, PF is associated with high morbidity and mortality [4-6].

It has been long known that inflammation plays a key role in the triggering and persistence of fibrotic processes in the lungs [7]. To this end, many inflammatory mediators such as damage-associated molecular patterns (DAMPs) and proinflammatory cytokines have been found to play a role in the exacerbation of fibrosis [8-12]. Extracellular cold-inducible RNA-binding protein (eCIRP) is a novel DAMP discovered by our lab to play a key role in sepsis, hemorrhagic shock, acute lung injury, renal and intestinal ischemia-reperfusion injuries, and ischemic stroke [13-17]. eCIRP induces these effects through its binding to the toll-like receptor 4 (TLR4) and specifically TLR4-myeloid differentiation 2 (MD2) complex [18].

While the effect of eCIRP in acute inflammation and acute lung injury has been studied, little is known about its role in chronic inflammatory diseases of the lungs, especially the development of PF. During the past decade, evidence has emerged that DAMPs play a key role in promoting exacerbation, remodeling, and silent progression of PF [8]. Furthermore, laboratory and genome-wide association studies have implicated the TLR4-MD2 complex to be a critical mediator of pulmonary fibrosis [19-22]. Hence, we decided to examine whether eCIRP plays any role in the pathogenesis of PF and whether blocking this effect by a small molecule can ameliorate the development of PF in a mouse model.

Materials and methods

Analysis of gene expression omnibus datasets

The expression datasets were obtained directly from the gene expression omnibus website (https://www.ncbi.nlm.nih.gov/geo) using the getGEO function of R (http://www.r-project.org/) 4.0.3 library called GEOquery [23]. After obtaining the datasets for both GSE98925 and GSE10667, they were each normalized to the median value across all samples using package limma workflow [24]. To correlate the normalized mRNA count of α-smooth muscle actin (α-SMA) and CIRP in gene expression data of GSE98925, ggscatter function of library ggpubr library was used by setting the correlation method to Pearson correlation, and the coefficient was obtained. To compare the difference between the normalized count of CIRP among stable IPF patients and those with acute exacerbation of IPF in gene expression data of GSE10667, an unpaired Student’s t-test was used.

Experimental animals and model of fibrosis

Wild type (WT) C57BL/6 mice (Jackson Laboratory) and CIRP-/- mice with C57BL/6 background originally obtained from Kumamoto University, Japan and maintained at the Feinstein Institutes for Medical Research [25] were used in this study. Ten to twelve week-old male WT and CIRP-/- mice (n = 10 mice per group) received subcutaneous (s.c.) injections of bleomycin (Gold Biotechnology, St. Louis, MO; 10 μg/g/day, 100 μl of 1 mg/ml solution per injection of a ~20 g mouse) (identified as WT Bleomycin and CIRP-/- Bleomycin group) or PBS (identified as WT Control and CIRP-/- Control group) daily for 10 non-consecutive days (five times per week for two weeks) as described [26]. Animals were monitored daily for changes in health and behavior. The ultrasound imaging was obtained at three weeks. Animals require no special housing and no special handling. Since pulmonary fibrosis is painless, no analgesics or anesthetics were used. Two WT Bleomycin mice developed two or more predetermined humane endpoints (minimal or absent activity, weight loss of ≥ 20%, hunched or recumbent posture, minimal or no response to stimuli, grimace score = 2, body condition score ≤ 2, and labored breathing or respiratory distress) on day 18 and were immediately euthanized and excluded from the analysis. No mice died before meeting criteria for euthanasia. The remaining mice were sacrificed on day 22, when the lungs were collected. The left lung was fixed in formalin for histological assessment; the right lung was used for qPCR (superior and middle lobes) and measurement of hydroxyproline content (inferior and post-caval lobes).

C23 peptide

C23 peptide (GRGFSRGGGDRGYGG) was synthesized by GenScript (Piscataway, NJ). C23 is a short 15-mer peptide derived from CIRP with a high affinity to the TLR4-MD2 complex [13]. This peptide has been shown to antagonize eCIRP on TLR4-MD2 complex and attenuate sepsis, hemorrhagic shock, lung injury, and renal and intestinal ischemia-reperfusion injury [27-30]. For the WT Bleomycin+C23 group, in addition to the bleomycin injection described above, mice were also s.c. injected with C23 peptide (8 μg/g/day) as previously described [14, 28] starting on day 10 from the start of the initial bleomycin injection until day 19.

Isolation and analysis of real-time quantitative polymerase chain reaction

At the end of the experiments, total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA) and reverse transcribed to cDNA using M-MLV (Moloney murine leukemia virus) reverse transcriptase (Applied Biosystems, Foster City, CA). Polymerase chain reactions (PCR) were carried out in a final volume of 10.5 μl which included 5 μl SYBR Green PCR master mix (Applied Biosystems), and 0.031 μM of both reverse and forward primer. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was used to normalize the amplification data and fold changes were calculated in comparison with WT Control mice using the 2(-ΔΔCt) method. The sequence of forward and reverse primers used were as follows: GAPDH; 5’-CATCACTGCCACCCAGAAGACTG-3’ (forward) and 5’-ATGCCAGTGAGCTTCCCGTTCAG-3’(reverse). α-SMA; 5’-TGACCCAGATTATGTTTGA-3’ (forward) and 5’-GCTGTTATAGGTGGTTTCG-3’ (reverse). Collagen type 1 alpha 1 (Col1a1); 5’-GCAAGAGGCGAGAGAGGTTT-3’ (forward) and 5’-GACCACGGGCACCATCTTTA-3’ (reverse). Collagen type 3 alpha 1 (Col3a1); 5’-AGGCTGAAGGAAACAGCAAA-3’ (forward) and 5’-TAGTCTCATTGCCTTGCGTG-3’ (reverse).

Hydroxyproline assay

Colorimetric hydroxyproline assay kit (Cambridge, UK—catalog number: ab222941) was used to measure hydroxyproline content from samples prepared from ~100 mg of lung tissue lysates from each mouse.

Pulmonary hypertension and echocardiography

At the end of experiments, prior to the collection of lung tissue from mice, pulmonary hypertension data was obtained using transthoracic echocardiography. Prior to performing echocardiography, mice were sedated using minimal isoflurane and maintained on a heated table. Echocardiography was conducted using a 40 MHz center frequency transducer coupled to a Vevo®3100 Imaging System (Fujifilm VisualSonics, Toronto, ON, Canada). Pulmonary acceleration time (PAT) and pulmonary ejection time (PET) were obtained and used to calculate the PAT/PET ratio, which correlates with inverse right ventricular pressure–an indicator of pulmonary hypertension [31, 32].

Lung histology and fibrosis scores

Lung tissues were obtained at the end of the experiment and were cut into 5-μm fragments, preserved in paraffin, and later stained with hematoxylin and eosin. Hübner’s modification of the Ashcroft method was used to calculate the fibrosis score [33]. Briefly, we used the following gradings: (0), normal lung; (1), isolated alveolar septa with minor fibrotic changes; (2), fibrotic changes of alveolar septa with knot-like formations; (3), continuous fibrotic walls of alveolar septa; (4), non-confluent fibrotic masses; (5), confluent fibrotic masses; (6), large continuous fibrotic masses; (7), air bubbles; (8) fibrous obliteration. The sections were reviewed under light microscopy (Nikon ECLIPSE Ti-S) at 200x magnification. For each staining section, four random sites were observed and scored; the mean score of four sites was used as the fibrosis score of each lung section. The sections were assessed by an investigator blinded to the study groups.

Statistical analysis

Data are expressed in the bar graphs as mean and standard deviation (SD), with individual values shown by colored points. The comparisons of WT and CIRP-/- mice’s molecular and physiological markers were performed using two-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test with the factors of two-way ANOVA being CIRP gene expression status (WT vs. CIRP-/-) and bleomycin exposure status (Bleomycin vs. Control). The comparison for those with the C23 treatment group was done via one-way ANOVA followed by Tukey’s multiple comparison test. Differences between the experimental groups reaching a p-value of 0.05 or less were considered statistically significant.

Ethics

The expression dataset comparisons used deidentified data publicly available at the gene expression omnibus website and, therefore did not require IRB approval. All experiments involving live animals were carried out in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals [34] and were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the Feinstein Institutes for Medical Research.

Results

The positive correlation of CIRP with α-SMA, and upregulated CIRP expression in the lungs of IPF patients during exacerbation

We examined two publicly available gene expression omnibus (GEO) profiles: GSE98925, containing the array profile of microdissection from multiple fibroblastic foci from the lung tissues of 13 IPF patients either during a biopsy or after lung explant, and GSE10667, containing the array profile of whole lung tissue samples from IPF patients either with biopsy or after lung explant. This included 23 stable IPF patients (UIP) and 8 patients with acute exacerbation (AEx). We sought a correlation between the normalized mRNA count of CIRP and α-SMA levels in GSE98925 data of fibroblastic foci. The analysis showed a positive correlation between CIRP and α-SMA levels (R = 0.39, p = 0.0017) (). It is important to note that the correlation held even after we removed the samples that were two standard deviations from the mean of each expression. Furthermore, we looked at the expression of CIRP mRNA in the tissue samples profile obtained from GSE10667, which showed a significant increase in the normalized CIRP mRNA in the lung samples during exacerbation (p<0.05) (). This analysis showed that not only does the expression of CIRP correlate with α-SMA in IPF patients, the levels of CIRP increases during acute exacerbation of IPF.

Molecular markers of fibrosis are ameliorated in CIRP-/- mice

To examine the fibrotic role of eCIRP, we examined the mRNA expression of α-SMA, Col1a1, and Col3a1, and the corresponding hydroxyproline content in the lung tissue of WT Control, WT Bleomycin, CIRP-/- Control, and CIRP-/- Bleomycin mice. Our analysis showed that there was a 10.65- and 4.27-fold increase in α-SMA and Col3a1 expressions respectively in WT mice when comparing Bleomycin vs. Control group (p = 0.0180 for α-SMA mRNA p = 0.0002 for Col3a1 mRNA), however, there was no significant increase seen in CIRP-/- mice. Furthermore, mRNA expressions of α-SMA and Col3a1 were attenuated by 89% and 64% (p = 0.0030 for α-SMA, p = 0.003 for Col3a1) in CIRP-/- Bleomycin mice compared to WT Bleomycin (). There was a 72.24-fold increase (p = 0.0208) seen in Col1a1 mRNA expression of WT mice when comparing Control with the Bleomycin group, however, no significant increase was seen in CIRP-/- mice. While Col1a1 mRNA expression level was not significantly different between CIRP-/- Bleomycin mice compared to WT Bleomycin (due to large standard deviation of Col1a1 mRNA expression in Bleomycin WT mice), there was a 64% decrease in the mean of Col1a1 mRNA expression in CIRP-/- Bleomycin mice (). Additionally, there was a 2.08-fold increase (p = 0.0003) seen in hydroxyproline content of WT mice when comparing Control with Bleomycin group and was not seen in CIRP-/- mice. The hydroxyproline content CIRP-/- Bleomycin group was attenuated by 40% (p = 0.0049) as compared to WT Bleomycin mice ().

Physiological and histological markers of fibrosis are ameliorated in CIRP-/- mice

We examined the PAT/PET ratio (a surrogate for pulmonary artery flow) using echocardiography in WT Control, WT Bleomycin, CIRP-/- Control, and CIRP-/- Bleomycin mice. Our analysis showed a decrease of 32.5% (p<0.0001) in the PAT/PET ratio of WT mice when comparing the Bleomycin vs. Control group. Furthermore, there was an increase of 30% (p = 0.0011) seen in the PAT/PET ratio when we compared WT Bleomycin with the CIRP-/- Bleomycin group (). When comparing the histological effects () there was a 5.93-fold (p<0.0001) increase in the fibrosis score of WT mice when we compared the Bleomycin and Control group, while this increase was only 1.76-fold (p = 0.0001) in CIRP-/- mice. Furthermore, there was a significant decrease of 37% (p<0.0001) in the fibrosis score when comparing CIRP-/- Bleomycin compared to WT Bleomycin mice ().

eCIRP antagonist C23 attenuates lung fibrosis

In order to determine the effect of eCIRP antagonist C23 on bleomycin-treated WT mice, we examined the mRNA expression of α-SMA, Col1a1, and Col3a1, and hydroxyproline content in the lung tissues. Our analysis showed that while there was a 10.65-, 72.24-, 4.27-, and 2.08-fold increases in mRNA expression of α-SMA, Col1a1, and Col3a1, and hydroxyproline content respectively when comparing WT Bleomycin and WT Control group (as seen in ), these increases were not seen when we compared WT Bleomycin+C23 to WT Control mice. Furthermore, α-SMA, Col1a1, and Col3a1 mRNA expressions, and hydroxyproline content were decreased by 96.5, 97.4, 57.8, and 54.6% (p = 0.0277 for α-SMA, p = 0.0190 for Col1a1, and p = 0.0046 for Col3a1 mRNA and p = 0.0002 for hydroxyproline content) when we compared WT Bleomycin+C23 to WT Bleomycin (Figs ).

Fig 2

Deficiency in CIRP attenuates molecular markers of lung fibrosis in mice exposed to bleomycin.

For α-SMA (A), Col1a1 (B), and Col3a1 (C) mRNA expression data, total RNA was isolated using Trizol reagent and reverse transcribed to cDNA using M-MLV (Moloney murine leukemia virus) reverse transcriptase. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) RNA was used to normalize the amplification data and fold changes were calculated in comparison with WT Control mice using the 2(-ΔΔCt) method. For the hydroxyproline assay, a calorimetric Hydroxyproline assay kit was used to measure hydroxyproline content from samples prepared from ~100 mg of lung tissue lysates from each mouse (D). * p<0.05 vs. Wild Type (WT) Control, # p<0.05 vs. WT Bleomycin. Data were analyzed using a two-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test with factors of two-way ANOVA being CIRP gene expression status (WT vs. CIRP-/-) and bleomycin exposure status (Bleomycin vs. Control).

Our analysis showed that while there was a 32.5% decrease in PAT/PET ratio when comparing WT Bleomycin to WT Control mice (as seen in ), this decrease was not seen when comparing WT Bleomycin+C23 with WT Control mice. Furthermore, there was an increase of 45% (p<0.0001) in the PAT/PET ratio when we compared WT Bleomycin+C23 with WT Bleomycin mice (). When we looked at the histological effects of the C23 treatment, there was a 5.93-fold (p<0.0001) increase in fibrosis score when we compared WT Bleomycin with WT Control (as seen in ), this increase was only 3.44 fold (p<0.0001) when we compared WT WT Bleomycin+C23 with WT Control (). Furthermore, we saw an attenuation of 42% (p<0.0001) when we compared concurrent C23 treatment as compared to those with bleomycin alone (WT Bleomycin+C23 vs. Bleomycin).

Fig 3

Deficiency in CIRP ameliorates physiological markers of fibrosis in mice exposed to bleomycin.

Pulmonary acceleration time (PAT)/pulmonary ejection time (PET) ratio (A) was obtained which correlates with inverse right ventricular pressure (a surrogate for pulmonary hypertension). 5-μm lung tissue fragments preserved in paraffin, and later stained with hematoxylin and eosin (B) were evaluated using Hübner’s modification of the Ashcroft fibrosis score (C). Four random sites were observed and scored under light microscopy at 200x magnification; the mean score of four sites was used as the fibrosis score of each lung section. Representative samples for the lung sections are shown at 400x from Wild Type (WT) Control, WT Bleomycin, CIRP-/- Control, and CIRP-/- Bleomycin mice (B). * p<0.05 vs. WT Control, # p<0.05 vs. WT Bleomycin.

Discussion

Pulmonary fibrosis is a devastating sequela of many chronic inflammatory diseases characterized by a progressive decline in lung volume capacity and resulting in high mortality [35, 36]. Currently, the few therapeutics developed to ameliorate PF only modestly alter its rapid progression [37]. Estimated mortality from pulmonary fibrosis is between 46.8 to 102.6 deaths per million and there has been an increase in recent decades [38, 39]. The elevated morbidity and mortality associated with PF underline the urgent need for more effective therapeutic approaches. Studies on the role of immune cells in PF indicate that while immune cells are prominent in the early phases of the fibrotic process, the factors released by these cells within the microenvironment have a long-lasting effect [40-42]. Specifically, uncontrolled activation of macrophages and fibroblasts by DAMPs starts an inflammatory cascade that further damages pulmonary tissues, causing the further release of more DAMPs in the tissue microenvironment creating a vicious cycle that culminates in fibrosis. DAMPs exert their effect on macrophages and fibroblasts mainly through TLRs [43]. The seminal work of Bhattacharyya et al. further specified that the effects attributed to PF are largely mediated through the TLR4-MD2 pathway [20, 42, 44].

One way to mitigate the effects of the fibrosis vicious cycle described above is to stop DAMPs with high affinity and efficacy in activating the TLR4-MD2 complex. Using surface plasmon resonance (SPR) analysis, our lab had previously shown that CIRP binds to the TLR4-MD2 complex, as well as to TLR4 and MD2 individually, with high affinity, suggesting that blocking eCIRP can ameliorate TLR4-MD2 complex signal activation [13]. Indeed, our investigation on the GEO GSE98925 mRNA profiles of samples from IPF patients’ fibroblastic foci showed that there is a correlation between the expression of CIRP and α-SMA. The progression of PF is characterized at the cellular level by the differentiation of fibroblastic cells into myofibroblasts, and α-SMA is a critical marker of myofibroblast differentiation [45]. Moreover, our analysis of GEO GSE10667 showed that the expression of CIRP is particularly elevated during exacerbation of IPF in lung tissue (). These findings are in line with the proposition that repetitive injury caused by acute exacerbation worsens PF not only in IPF patients but also in other chronic diseases affecting the lung [46-52]. Furthermore, in spite the lack of evidence for a causative effect of inflammation in IPF, a recent study has shown that IPF patients with elevated serum eCIRP levels had increased disease progression and all-cause mortality [53]. Taken together, these clinical observations lend support to further investigating eCIRP in a mouse model of PF as a potential target in ameliorating the fibrotic process.

The release of proinflammatory cytokines like TNF-α, IL-1β, and IL-6 in the lung tissue microenvironment by stimulated macrophages and fibroblasts contributes to the persistence of lung fibrosis by activating fibroblasts in an autocrine/paracrine fashion [10, 54–58]. Our lab has previously shown that eCIRP is a potent inducer of TNF-α, IL-1β, and IL-6 in macrophages in a TLR4 dependent manner, and that CIRP-/- mice have an ameliorated response to the acute injury brought on by the storm of these proinflammatory cytokines [13, 15, 18, 59]. In our recently published observations, we have seen that eCIRP is a powerful inducer of these cytokines in pulmonary fibroblasts as well [60]. Therefore, we conjectured that eCIRP can promote the persistent autocrine/paracrine activation of fibroblasts by inducing the release of proinflammatory cytokines from macrophages and fibroblasts. We focused our attention on CIRP-/- mice to determine if there is an attenuated response to the chronic inflammatory models of murine PF.

Rampant collagen deposition, marked by an increase in expression of Col1a1 and Col3a1, is the hallmark of fibrosis in the lung tissue extracellular microenvironment [61-64]. In addition, hydroxyproline, a major component of all types of fibrillar collagen, correlates well with the amount of stable collagen in the lung tissue and is widely used to assess the degree of PF [65, 66]. One of the devastating complications of chronic diseases causing fibrosis in the lungs is the development of pulmonary hypertension [67-69]. We measured pulmonary hypertension by PAT/PET ratio, which is one of the most accurate non-invasive surrogates for pulmonary artery flow correlating with the inverse of pulmonary hypertension [31, 32]. As postulated, CIRP-/- mice lung showed ameliorated fibrotic response to bleomycin-induced PF shown by a reduction in mRNA expression of α-SMA, Col1a1, and Col3a1, and hydroxyproline content levels in the lung tissue as compared to WT mice (). We also showed that this effect is not limited to molecular markers as the physiologic impact of PF is also attenuated in CIRP-/- mice by having an ameliorated pulmonary hypertension, and fibrosis score ().

The inflammatory effect of eCIRP is caused in an extracellular milieu partially through a TLR4-MD2 complex [18] and we have shown that the CIRP-derived peptide C23 acts as a competitive antagonist inhibiting the binding of eCIRP to the TLR4-MD2 complex [13]. Since we have demonstrated that treatment with C23 attenuates inflammation and ameliorates clinically relevant endpoints in various animal models shown to be aggravated by eCIRP [28, 30, 70], we ventured to see if blocking eCIRP using C23 peptide on TLR4-MD2 complex can ameliorate the bleomycin-induced fibrotic response in the lung. We have already shown that the inflammatory pathways and cytokines are at their peak of expression on day 14 after the start of bleomycin injection and there is a drop in expression of these pathways and cytokines on day 21 [60]. This is in line with Raventti et al., who showed there is an increase in infiltration of total white blood cells, neutrophils, and macrophages in lung tissue at day 14 of bleomycin injection that decreases on day 21 [71]. Therefore, we hypothesized that by blocking eCIRP around this day, we can reduce the inflammatory phase of bleomycin-induced lung fibrosis and ameliorate the fibrotic response. Indeed, our results show that molecular and physiological markers of PF can be ameliorated in the murine model of bleomycin-induced PF by treatment of C23 from day 10 to day 19 after the first injection of bleomycin (Figs ). Not much is known about C23 other than its sequence, the affinity of its binding to TLR4, and its efficacy in reducing eCIRP-mediated inflammation. Future studies should focus on C23’s pharmacokinetics, immunogenicity, and possible pharmacotoxicity, as well as its potential administration by inhalation.

However, we realize this study has some limitations. The bleomycin model of PF is widely used for studies of the pathogenesis of the fibrotic process and of new treatments for PF, but it is not adequate for investigating the etiology of PF in humans. While we have shown that blocking eCIRP’s effect on the TLR4-MD2 complex attenuates the fibrotic effect of bleomycin, we have not directly assessed whether this comes as a result of blocking the inflammatory phase of bleomycin-induced pulmonary fibrosis as speculated. While studies using CIRP-/- mice cannot determine whether the attenuated PF phenotype is due to the intra- or extracellular effects of CIRP, we have shown that blocking eCIRP with C23 ameliorates the bleomycin-induced PF, thus demonstrating the relevance of the extracellular effects of eCIRP. However, given that the injections were not done in parallel between the groups, there is a potential for a cage effect that can introduce bias into our comparisons. While we have evaluated mRNA expression of CIRP in IPF patients in publicly available GEO datasets, we could not measure eCIRP protein level in the lung tissue interstitial fluid. Nonetheless, our previous studies showed a strong correlation between increased mRNA expression of CIRP and increased eCIRP protein in serum and cell culture supernatants [13, 72–74]. Future studies obtaining eCIRP levels in the lung tissue and bronchoalveolar lavage fluid of patients with pulmonary fibrosis during exacerbations should provide further evidence that the contribution of CIRP to pulmonary fibrosis is at the extracellular level.

In conclusion, we here demonstrate for the first time that CIRP plays a crucial role in PF. We demonstrate that eCIRP contributes to PF through its effect in the extracellular microenvironment. Furthermore, we showed that the eCIRP competitive antagonist C23 can ameliorate the fibrotic response. Although the precise molecular mechanism by which eCIRP contributes to PF remains to be elucidated, we hypothesize that it is likely by dampening the inflammatory phase of fibrotic response in tissue macrophages and fibroblasts, which results in the halting of autocrine/paracrine activation to myofibroblasts. Therapeutically targeting eCIRP not only shows promise in the treatment of exacerbations of PF in chronic inflammatory diseases of the lung but also attenuating the overall progression of PF.

Fig 1 data and statistical analysis.

This table contains the data and statistical analysis used in Fig 1.

Fig 1

CIRP mRNA expression correlates with α-SMA in IPF patients and is increased during acute exacerbation of IPF.

Examinations of two publicly available gene expression omnibus (GEO) profiles: GSE98925 and GSE10667 (insert): After obtaining mRNA expression data using the getGEO function, expressions were normalized across all samples using the package limma workflow. The figure shows Pearson correlation and the coefficient (R = 0.39) obtained between mRNA expression of CIRP and α-SMA, along with p-value (p = 0.0017) shown for GSE98925, which is the mRNA array profile of microdissection from multiple fibroblastic foci from the lung tissues of 13 IPF patients either from the biopsy or after lung explantation. The insert shows the difference between the normalized CIRP mRNA in stable IPF patients (UIP) vs. those with acute exacerbation of IPF (AEx) in data from GSE10667. Unpaired Student’s t-test was used to determine the significance. * p<0.05 vs. UIP. The sample GSM269765 was removed due to normalized CIRP mRNA for that sample being more than 3 standard deviations away from the means.

(XLSX)

Click here for additional data file.

Fig 2 data and statistical analysis.

This table contains the data and statistical analysis used in Fig 2.

(XLSX)

Click here for additional data file.

Fig 3 data and statistical analysis.

This table contains the data and statistical analysis used in Fig 3.

(XLSX)

Click here for additional data file.

Fig 4 data and statistical analysis.

This table contains the data and statistical analysis used in Fig 4.

Fig 4

The eCIRP antagonist C23 ameliorates molecular markers of fibrosis in mice exposed to bleomycin.

For α-SMA (A), Col1a1 (B), and Col3a1 (C) mRNA expression data, total RNA was isolated using Trizol reagent and reverse transcribed to cDNA using M-MLV (Moloney murine leukemia virus) reverse transcriptase. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) RNA was used to normalize the amplification data and fold changes were calculated in comparison with WT Control mice, using the 2(-ΔΔCt) method. For the hydroxyproline assay, the calorimetric Hydroxyproline assay was used to measure hydroxyproline content (D) from samples prepared from ~100 mg of lung tissue lysates from each mouse. * p<0.05 vs. Wild Type (WT) Control, # p<0.05 vs. WT Bleomycin. Data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test. WT Bleomycin and WT Control groups are identical to that of Fig 2.

(XLSX)

Click here for additional data file.

Fig 5 data and statistical analysis.

This table contains the data and statistical analysis used in Fig 5.

Fig 5

The eCIRP antagonist C23 ameliorates physiological markers of fibrosis in mice exposed to bleomycin.

PAT/PET ratio (A) was calculated which correlates with inverse right ventricular pressure (a surrogate for pulmonary hypertension). 5-μm lung tissue fragments preserved in paraffin and later stained with hematoxylin and eosin (B) were evaluated using Hübner’s modification of the Ashcroft fibrosis score (C). Four random sites were observed and scored under light microscopy at 200x magnification; the mean score of four random sites was used as the fibrosis score of each lung section. The representative sample for the lung sections is shown at 400x from Wild Type (WT) Control, WT Bleomycin, and WT Bleomycin+C23 mice (B). * p<0.05 vs. WT Control, # p<0.05 vs. WT Bleomycin. WT Bleomycin and WT Control groups are identical to that of Fig 3.

(XLSX)

Click here for additional data file.

16 Feb 2022

The Role of eCIRP in Bleomycin-Induced Pulmonary Fibrosis in Mice

PLOS ONE

Dear Dr. Brenner

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by June 7th 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Manjula Karpurapu

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf".

2. In your Methods section, please provide additional details regarding bleomycin and C23 peptide used in your study and ensure you have described the source. For more information regarding PLOS' policy on materials sharing and reporting, see https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-materials.

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

5. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

_______________________________________________________________________

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting and well-designed combination of human data and murine work. The authors show that eCIRP contributes to pathological manifestations of bleomycin-induced pulmonary fibrosis in mice and that small molecule blockade attenuates bleomycin effects.

The following is needed:

1) Clarify the established finding that no clear causal role is known for active inflammation in IPF.

2) Remove discussion of Covid-19 unless it is directly relevant here.

3) State that the assessment of fibrosis in mice was performed by persons blinded to the treatment/conditions. If not, then this assessment should be performed again in blinded fashion.

4) Make it very clear that studies in this mouse model cannot be used to make conclusions about human PF etiopathogenesis.

Minor: In "Materials and Methods" The expression datasets were was obtained - please fix: The expression datasets were obtained

Bottom of page 6: Ten to twelve weeks-old male - please fix: Ten to twelve week-old male

Page 11: that not only the expression of CIRP correlates - please fix: that not only does the expression of CIRP correlate

Reviewer #2: This paper is very straight forward and easy to follow. Some minor revisions include:

1. There is a duplicate sentence in the abstract. Please edit.

2. Clarify the results section of the abstract, expression of CIRP increased during exacerbation of PF in human lung tissues. Unless you also tracked CIRP expression in mice over the course of bleo treatment and not just at day 22.

3. Clarify in methods what was harvested for qPCR, mouse lung and what lobes since portions were taken for histology and hydroxyproline assays?

4. Did you notice any heterogeneity in the histological sections of mouse lung tissue? Could this variability account for the wide spread in your WT Bleo mice? Could you speak to why you might see such variability in these samples? Also was the scoring of the fibrotic lung tissue blinded?

5. I would be curious to see if preemptive treatment or co-treatment with C23 with the bleo could further reduce or prevent the development of the fibrotic phenotype observed.

6. I recommend including a section in the discussion about the application of C23 in patient treatment, potential issues, clinical use etc. to frame what is known and still needs to be understood.

The authors clearly defined their study, did not overreach their claims, and did a nice job of laying out the limitations and next steps for this line of work.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.